Brief: BioArctic Reports Q4 Sales Of Leqembi At SEK 20.7 Billion
06/02/2026 11:03
Corrects currency in headline Feb 6 (Reuters) - BioArctic AB BIOAb.ST: SALES OF LEQEMBI TOTALED 20.7 BILLION YEN IN THE FOURTH QUARTER 2025 RECEIVES SEK 127 MILLION ROYALTY FROM LEQEMBI SALES Source text: ID:nWkr74lwNb Further company coverage: [BIOAb.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln